Cost-effectiveness of asenapine in the treatment of bipolar disorder in canada

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Lachaine, Jean ^a   Beauchemin, Catherine ^a   Mathurin, Karine ^a   Gilbert, Dominique ^b   Beillat, Maud ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b H LUNDBECK A S   (Denmark)

^c Lundbeck   (France)

Author keywords

Antipsychotic; Asenapine; Bipolar disorder; Canada; Cost effectiveness; Cost utility; Olanzapine

Indexed keywords

ASENAPINE; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; CANADA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIDDEN MARKOV MODEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; PROBABILITY; PSYCHOPHARMACOTHERAPY; QUALITY ADJUSTED LIFE YEAR; WEIGHT GAIN; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CANADA; COST-BENEFIT ANALYSIS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; WEIGHT GAIN;

EID: 84892665079     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-14-16     Document Type: Article

References (57)

1. Bauer M, Pfennig A. Epidemiology of bipolar disorders. Epilepsia 2005, 46(Suppl 4):8-13.
2. Belmaker RH. Bipolar disorder. N Engl J Med 2004, 351(5):476-486. 10.1056/NEJMra035354, 15282355.
3. Culver JL, Arnow BA, Ketter TA. Bipolar disorder: improving diagnosis and optimizing integrated care. J Clin Psychol 2007, 63(1):73-92. 10.1002/jclp.20333, 17115430.
4. Schaffer A, Cairney J, Cheung A, Veldhuizen S, Levitt A. Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry 2006, 51(1):9-16.
5. Oquendo MA, Waternaux C, Brodsky B, Parsons B, Haas GL, Malone KM, Mann JJ. Suicidal behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters. J Affect Disord 2000, 59(2):107-117. 10.1016/S0165-0327(99)00129-9, 10837879.
6. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349(9063):1436-1442. 10.1016/S0140-6736(96)07495-8, 9164317.
7. Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002, 180:227-233. 10.1192/bjp.180.3.227, 11872515.
8. Laxman KE, Lovibond KS, Hassan MK. Impact of bipolar disorder in employed populations. Am J Manag Care 2008, 14(11):757-764.
9. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005, 66(1):111-121. 10.4088/JCP.v66n0116, 15669897.
10. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162(7):1351-1360. 10.1176/appi.ajp.162.7.1351, 15994719.
11. Woodward TC, Tafesse E, Quon P, Lazarus A. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. Pharmacoeconomics 2010, 28(9):751-764. 10.2165/11538350-000000000-00000, 20623994.
12. Calvert NW, Burch SP, Fu AZ, Reeves P, Thompson TR. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm 2006, 12(4):322-330.
13. McKendrick J, Cerri KH, Lloyd A, D'Ausilio A, Dando S, Chinn C. Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. J Psychopharmacol 2007, 21(6):588-596.
14. Fajutrao L, Paulsson B, Liu S, Locklear J. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. Clin Ther 2009, 31(Pt 1):1456-1468.
15. Kasteng F, Eriksson J, Sennfalt K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand 2011, 124(3):214-225. 10.1111/j.1600-0447.2011.01716.x, 21609324.
16. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009, 11(7):673-686. 10.1111/j.1399-5618.2009.00748.x, 19839993.
17. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 2009, 11(8):815-826. 10.1111/j.1399-5618.2009.00749.x, 19832806.
18. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010, 122(1-2):27-38.
19. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010, 126(3):358-365. 10.1016/j.jad.2010.04.005, 20537396.
20. Johnson FR, Ozdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med Care 2007, 45(6):545-552. 10.1097/MLR.0b013e318040ad90, 17515782.
21. Oguma Y, Sesso HD, Paffenbarger RS, Lee IM. Weight change and risk of developing type 2 diabetes. Obes Res 2005, 13(5):945-951. 10.1038/oby.2005.109, 15919849.
22. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 1995, 273(6):461-465.
23. Williams PT. Increases in weight and body size increase the odds for hypertension during 7 years of follow-up. Obesity (Silver Spring) 2008, 16(11):2541-2548. 10.1038/oby.2008.396, 18756262.
24. Huang Z, Willett WC, Manson JE, Rosner B, Stampfer MJ, Speizer FE, Colditz GA. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998, 128(2):81-88. 10.7326/0003-4819-128-2-199801150-00001, 9441586.
25. Galanis DJ, Harris T, Sharp DS, Petrovitch H. Relative weight, weight change, and risk of coronary heart disease in the Honolulu Heart Program. Am J Epidemiol 1998, 147(4):379-386. 10.1093/oxfordjournals.aje.a009460, 9508105.
26. Asplund K, Karvanen J, Giampaoli S, Jousilahti P, Niemela M, Broda G, Cesana G, Dallongeville J, Ducimetriere P, Evans A, et al. Relative risks for stroke by age, sex, and population based on follow-up of 18 European populations in the MORGAM Project. Stroke 2009, 40(7):2319-2326. 10.1161/STROKEAHA.109.547869, 19520994.
27. Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care 2005, 28(6):1339-1345. 10.2337/diacare.28.6.1339, 15920049.
28. Public Health Agency of Canada Report from the Canadian Chronic Disease Surveillance System: Hypertension in Canada, 2010. Chronic Disease Surveillance Division 2010, 28. Ottawa: Public Health Agency of Canada, Available from: http://www.phac-aspc.gc.ca/cd-mc/cvd-mcv/ccdss-snsmc-2010/pdf/CCDSS_HTN_Report_FINAL_EN_20100513.pdf., Public Health Agency of Canada.
29. Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med 2001, 161(2):242-247. 10.1001/archinte.161.2.242, 11176738.
30. Biagini E, Elhendy A, Schinkel AF, Rizzello V, van Domburg RT, Krenning BJ, Schouten O, Sozzi FB, Branzi A, Rocchi G, et al. Comparison of all-cause mortality in women with known or suspected coronary artery disease referred for dobutamine stress echocardiography with normal versus abnormal test results. Am J Cardiol 2005, 95(9):1072-1075. 10.1016/j.amjcard.2004.12.061, 15842974.
31. Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke 2001, 32(9):2131-2136. 10.1161/hs0901.094253, 11546907.
32. Revicki DA, Hanlon J, Martin S, Gyulai L, Nassir Ghaemi S, Lynch F, Mannix S, Kleinman L. Patient-based utilities for bipolar disorder-related health states. J Affect Disord 2005, 87(2-3):203-210.
33. Schultz SE, Kopec JA. Impact of chronic conditions. Health Rep 2003, 14(4):41-53.
34. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997, 170:205-228.
35. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010, 43(4):138-146.
36. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-1223. 10.1056/NEJMoa051688, 16172203.
37. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164(7):1050-1060. 10.1176/appi.ajp.164.7.1050, 17606657.
38. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006, 163(4):611-622. 10.1176/appi.ajp.163.4.611, 16585435.
39. National Collaborating Centre for Mental Health (UK) Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet]. 2009, Leicester (UK): British Psychological Society, Mar. (NICE Clinical Guidelines, No. 82.) Available from: http://www.ncbi.nlm.nih.gov/books/NBK11681/, National Collaborating Centre for Mental Health (UK).
40. Consumer Price Index, Health Care: CANSIM Table 326-0020.
41. Régie de l'assurance maladie du Québec List of Medications. 33, Last updated on 3 October 2013. Quebec?: Bibliothèque et Archives nationales du Québec, 2011. Available from: https://www.prod.ramq.gouv.qc.ca/DPI/PO/Commun/PDF/Liste_Med/Liste_Med/liste_med_2011_10_03_en.pdf, Régie de l'assurance maladie du Québec.
42. Régie de l'assurance maladie du Québec Manuel des médecins spécialistes. 2011, Régie de l'assurance maladie du Québec.
43. Public Health Agency of Canada Tracking Heart Disease and Stroke in Canada. 2009, Ottawa, Public Health Agency of Canada.
44. Patra J, Popova S, Rhem J, Bondy S, Flint R, Giesbrecht N. Economic Cost of Chronic Disease in Canada: 1995-2003 2007
45. Heart and Stroke Foundation of Canada The Growing Burden of Heart Disease and Stroke in Canada 2003. 2003, Ottawa, Canada, In vol. 1-896242-30-8, Heart and Stroke Foundation of Canada.
46. Public Health Agency of Canada Diabetes in Canada:Highlights from the National Diabetes Surveillance System 2004 - 2005. 2008, Ottawa: PHAC, Public Health Agency of Canada.
47. Goeree R, Blackhouse R, Petrovic R, Salama S. Cost of stroke in Canada: a 1-year prospective study. J Med Econ 2005, 8:147-167.
48. Canadian Psychiatric Association Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005, 50(13 Suppl 1):7S-57S. Canadian Psychiatric Association.
49. Wilkins K, Park E. Home care in Canada. Health Rep 1998, 10(1):29-37. ENG); 31-40(FRE.
50. Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004, 71(1):155-165. 10.1016/j.schres.2003.10.010, 15374583.
51. Statistics Canada Life Tables, Canada, provinces and territories, 2000-2002 (Catalogue no. 84-537-XIE). 2006, Ottawa: Minister of Industry E, Statistics Canada.
52. Statistics Canada Death and mortality rates, by selected groupes causes, age, group and sex, Table 102-0551 (Catalogue no. 84F0209X). 2007, Ottawa, Minister of Industry, Statistics Canada.
53. McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract 2010, 16(4):744-755. 10.1111/j.1365-2753.2009.01189.x, 20545800.
54. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008, 10(7):788-797. 10.1111/j.1399-5618.2008.00625.x, 19032710.
55. Treuer T, Hoffmann VP, Chen AK, Irimia V, Ocampo M, Wang G, Singh P, Holt S. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry 2009, 10(4 Pt 3):729-740.
56. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15(7):820-825. 10.2337/diacare.15.7.820, 1516498.
57. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991, 151(6):1141-1147. 10.1001/archinte.1991.00400060077013, 2043016.